|
|
Blood, 15 January 2004, Vol. 103, No. 2, pp. 689-694.
Prepublished online as a Blood First Edition Paper on September 25, 2003; DOI 10.1182/blood-2003-06-2043.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival
Anne J. Novak,
Jaime R. Darce,
Bonnie K. Arendt,
Brandon Harder,
Kathy Henderson,
Wayne Kindsvogel,
Jane A. Gross,
Philip R. Greipp, and
Diane F. Jelinek
From the Departments of Immunology and Internal Medicine, Mayo Graduate and Medical Schools, Mayo Clinic, Rochester, MN; and Zymogenetics, Seattle, WA.
Multiple myeloma (MM) is a progressive disease that is thought to result from multiple genetic insults to the precursor plasma cell that ultimately affords the tumor cell with proliferative potential despite its differentiated phenotype and resistance to undergoing apoptosis. Altered expression of antiapoptotic factors as well as growth factors have been described in a significant number of patients. However, the key regulatory elements that control myeloma development and progression remain largely undefined. Because of the knowledge that B-lymphocyte stimulator (BLyS), a tumor necrosis factor (TNF) family member shown to be critical for maintenance of normal B-cell development and homeostasis, promotes the survival of malignant B cells, we began a coordinated study of BLyS and its receptors in MM. All MM cells studied expressed one or more of 3 known receptors (B-cell maturation antigen [BCMA], transmembrane activator and CAML interactor [TACI], and B-cell activating factor receptor [BAFF-R]) for BLyS; however, the pattern of expression was variable. Additionally, we provide evidence that BLyS can modulate the proliferative capacity and survival of MM cells. Finally, we provide evidence that BLyS is expressed by MM cells and is present in the bone marrow of patients with MM. Expression of BCMA, TACI, and BAFF-R by MM taken together with the ability of BLyS to support MM cell growth and survival has exciting implications because they may be potential therapeutic targets.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. S. Kim, J.-Y. Park, I. Jou, and S. M. Park
Functional implication of BAFF synthesis and release in gangliosides-stimulated microglia
J. Leukoc. Biol.,
August 1, 2009;
86(2):
349 - 359.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gupta, S. R. Dillon, S. C. Ziesmer, A. L. Feldman, T. E. Witzig, S. M. Ansell, J. R. Cerhan, and A. J. Novak
A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation
Blood,
May 21, 2009;
113(21):
5206 - 5216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Novak, S. L. Slager, Z. S. Fredericksen, A. H. Wang, M. M. Manske, S. Ziesmer, M. Liebow, W. R. Macon, S. R. Dillon, T. E. Witzig, et al.
Genetic Variation in B-Cell-Activating Factor Is Associated with an Increased Risk of Developing B-Cell Non-Hodgkin Lymphoma
Cancer Res.,
May 15, 2009;
69(10):
4217 - 4224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Sprynski, D. Hose, L. Caillot, T. Reme, J. D. Shaughnessy Jr, B. Barlogie, A. Seckinger, J. Moreaux, M. Hundemer, M. Jourdan, et al.
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor
Blood,
May 7, 2009;
113(19):
4614 - 4626.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Salzer, C. Bacchelli, S. Buckridge, Q. Pan-Hammarstrom, S. Jennings, V. Lougaris, A. Bergbreiter, T. Hagena, J. Birmelin, A. Plebani, et al.
Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes
Blood,
February 26, 2009;
113(9):
1967 - 1976.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Good, D. T. Avery, and S. G. Tangye
Resting Human Memory B Cells Are Intrinsically Programmed for Enhanced Survival and Responsiveness to Diverse Stimuli Compared to Naive B Cells
J. Immunol.,
January 15, 2009;
182(2):
890 - 901.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. Khuda, W. M. Loo, S. Janz, B. Van Ness, and L. D. Erickson
Deregulation of c-Myc Confers Distinct Survival Requirements for Memory B Cells, Plasma Cells, and Their Progenitors
J. Immunol.,
December 1, 2008;
181(11):
7537 - 7549.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Carbonatto, P. Yu, M. Bertolino, E. Vigna, S. Steidler, L. Fava, C. Daghero, B. Roattino, M. Onidi, M. Ardizzone, et al.
Nonclinical Safety, Pharmacokinetics, and Pharmacodynamics of Atacicept
Toxicol. Sci.,
September 1, 2008;
105(1):
200 - 210.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Hardenberg, L. Fernandez, J. Hendriks, K. Chebli, C. Jacquet, M. Sitbon, M. Hahne, and J. P. Medema
APRIL facilitates viral-induced erythroleukemia but is dispensable for T cell immunity and lymphomagenesis
J. Leukoc. Biol.,
August 1, 2008;
84(2):
380 - 388.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bossen, T. G. Cachero, A. Tardivel, K. Ingold, L. Willen, M. Dobles, M. L. Scott, A. Maquelin, E. Belnoue, C.-A. Siegrist, et al.
TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts
Blood,
February 1, 2008;
111(3):
1004 - 1012.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Mahtouk, D. Hose, J. De Vos, J. Moreaux, M. Jourdan, J. F. Rossi, T. Reme, H. Goldschmidt, and B. Klein
Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications
Clin. Cancer Res.,
December 15, 2007;
13(24):
7289 - 7295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Darce, B. K. Arendt, X. Wu, and D. F. Jelinek
Regulated Expression of BAFF-Binding Receptors during Human B Cell Differentiation
J. Immunol.,
December 1, 2007;
179(11):
7276 - 7286.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Ryan, M. Hering, D. Peckham, C. F. McDonagh, L. Brown, K. M. Kim, D. L. Meyer, R. F. Zabinski, I. S. Grewal, and P. J. Carter
Antibody targeting of B-cell maturation antigen on malignant plasma cells
Mol. Cancer Ther.,
November 1, 2007;
6(11):
3009 - 3018.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Neri, S. Kumar, M. T. Fulciniti, S. Vallet, S. Chhetri, S. Mukherjee, Y. Tai, D. Chauhan, P. Tassone, S. Venuta, et al.
Neutralizing B-Cell Activating Factor Antibody Improves Survival and Inhibits Osteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model
Clin. Cancer Res.,
October 1, 2007;
13(19):
5903 - 5909.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. G. Mueller, C. Boix, W.-H. Kwan, C. Daussy, E. Fournier, W. H. Fridman, and T. J. Molina
Critical role of monocytes to support normal B cell and diffuse large B cell lymphoma survival and proliferation
J. Leukoc. Biol.,
September 1, 2007;
82(3):
567 - 575.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Darce, B. K. Arendt, S. K. Chang, and D. F. Jelinek
Divergent Effects of BAFF on Human Memory B Cell Differentiation into Ig-Secreting Cells
J. Immunol.,
May 1, 2007;
178(9):
5612 - 5622.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Oki, G. V. Georgakis, T.-S. Migone, L. W. Kwak, and A. Younes
Prognostic significance of serum B-lymphocyte stimulator level in Hodgkin's lymphoma
Haematologica,
February 1, 2007;
92(2):
269 - 270.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kothlow, I. Morgenroth, Y. Graef, K. Schneider, I. Riehl, P. Staeheli, P. Schneider, and B. Kaspers
Unique and conserved functions of B cell-activating factor of the TNF family (BAFF) in the chicken
Int. Immunol.,
February 1, 2007;
19(2):
203 - 215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Chiu, W. Xu, B. He, S. R. Dillon, J. A. Gross, E. Sievers, X. Qiao, P. Santini, E. Hyjek, J.-w. Lee, et al.
Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL
Blood,
January 15, 2007;
109(2):
729 - 739.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Sene, N. Limal, P. Ghillani-Dalbin, D. Saadoun, J.-C. Piette, and P. Cacoub
Hepatitis C virus-associated B-cell proliferation--the role of serum B lymphocyte stimulator (BLyS/BAFF)
Rheumatology,
January 1, 2007;
46(1):
65 - 69.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Schwaller, P. Schneider, P. Mhawech-Fauceglia, T. McKee, S. Myit, T. Matthes, J. Tschopp, O. Donze, F.-A. Le Gal, and B. Huard
Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness
Blood,
January 1, 2007;
109(1):
331 - 338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. K. Chang, B. K. Arendt, J. R. Darce, X. Wu, and D. F. Jelinek
A role for BLyS in the activation of innate immune cells
Blood,
October 15, 2006;
108(8):
2687 - 2694.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Becker-Merok, C Nikolaisen, and H C Nossent
B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time
Lupus,
September 1, 2006;
15(9):
570 - 576.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Kukreja, A. Hutchinson, K. Dhodapkar, A. Mazumder, D. Vesole, R. Angitapalli, S. Jagannath, and M. V. Dhodapkar
Enhancement of clonogenicity of human multiple myeloma by dendritic cells
J. Exp. Med.,
August 7, 2006;
203(8):
1859 - 1865.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-T. Tai, X.-F. Li, I. Breitkreutz, W. Song, P. Neri, L. Catley, K. Podar, T. Hideshima, D. Chauhan, N. Raje, et al.
Role of B-Cell-Activating Factor in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment.
Cancer Res.,
July 1, 2006;
66(13):
6675 - 6682.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Fu, Y.-C. Lin-Lee, L. V. Pham, A. Tamayo, L. Yoshimura, and R. J. Ford
Constitutive NF-{kappa}B and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas
Blood,
June 1, 2006;
107(11):
4540 - 4548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Bischof, S. F. Elsawa, G. Mantchev, J. Yoon, G. E. Michels, A. Nilson, S. L. Sutor, J. L. Platt, S. M. Ansell, G. von Bulow, et al.
Selective activation of TACI by syndecan-2
Blood,
April 15, 2006;
107(8):
3235 - 3242.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. F. Elsawa, A. J. Novak, D. M. Grote, S. C. Ziesmer, T. E. Witzig, R. A. Kyle, S. R. Dillon, B. Harder, J. A. Gross, and S. M. Ansell
B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia
Blood,
April 1, 2006;
107(7):
2882 - 2888.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Matsumoto and M. Abe
Myeloma-Bone Interaction: A Vicious Cycle
IBMS BoneKEy,
March 1, 2006;
3(3):
8 - 14.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Novak, D. M. Grote, S. C. Ziesmer, M. P. Kline, M. K. Manske, S. Slager, T. E. Witzig, T. Shanafelt, T. G. Call, N. E. Kay, et al.
Elevated Serum B-Lymphocyte Stimulator Levels in Patients With Familial Lymphoproliferative Disorders
J. Clin. Oncol.,
February 20, 2006;
24(6):
983 - 987.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Yang, H. Hase, D. Legarda-Addison, L. Varughese, B. Seed, and A. T. Ting
B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells
J. Immunol.,
September 1, 2005;
175(5):
2814 - 2824.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Shaughnessy Jr
APRIL showers cause CLL and myeloma to flower
Blood,
August 1, 2005;
106(3):
766 - 767.
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Zhang, C.-S. Park, S.-O. Yoon, L. Li, Y.-M. Hsu, C. Ambrose, and Y. S. Choi
BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors
Int. Immunol.,
June 1, 2005;
17(6):
779 - 788.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. N. Pearse, S. L. Swendeman, Y. Li, D. Rafii, and B. L. Hempstead
A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival
Blood,
June 1, 2005;
105(11):
4429 - 4436.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bellucci, E. P. Alyea, S. Chiaretti, C. J. Wu, E. Zorn, E. Weller, B. Wu, C. Canning, R. Schlossman, N. C. Munshi, et al.
Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor
Blood,
May 15, 2005;
105(10):
3945 - 3950.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ingold, A. Zumsteg, A. Tardivel, B. Huard, Q.-G. Steiner, T. G. Cachero, F. Qiang, L. Gorelik, S. L. Kalled, H. Acha-Orbea, et al.
Identification of proteoglycans as the APRIL-specific binding partners
J. Exp. Med.,
May 2, 2005;
201(9):
1375 - 1383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Ogden, J. D. Pound, B. K. Batth, S. Owens, I. Johannessen, K. Wood, and C. D. Gregory
Enhanced Apoptotic Cell Clearance Capacity and B Cell Survival Factor Production by IL-10-Activated Macrophages: Implications for Burkitt's Lymphoma
J. Immunol.,
March 1, 2005;
174(5):
3015 - 3023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Huang, M. Di Liberto, A. F. Cunningham, L. Kang, S. Cheng, S. Ely, H.-c. Liou, I. C. M. MacLennan, and S. Chen-Kiang
Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1
PNAS,
December 21, 2004;
101(51):
17789 - 17794.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Q. Zhang, C. Okumura, T. McCarty, M. S. Shin, P. Mukhopadhyay, M. Hori, T. A. Torrey, Z. Naghashfar, J. X. Zhou, C. H. Lee, et al.
Evidence for Selective Transformation of Autoreactive Immature Plasma Cells in Mice Deficient in Fasl
J. Exp. Med.,
December 6, 2004;
200(11):
1467 - 1478.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Novak, D. M. Grote, M. Stenson, S. C. Ziesmer, T. E. Witzig, T. M. Habermann, B. Harder, K. M. Ristow, R. J. Bram, D. F. Jelinek, et al.
Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome
Blood,
October 15, 2004;
104(8):
2247 - 2253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ramanujam, X. Wang, W. Huang, L. Schiffer, C. Grimaldi, A. Akkerman, B. Diamond, M. P. Madaio, and A. Davidson
Mechanism of Action of Transmembrane Activator and Calcium Modulator Ligand Interactor-Ig in Murine Systemic Lupus Erythematosus
J. Immunol.,
September 1, 2004;
173(5):
3524 - 3534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W Stohl
A therapeutic role for BLyS antagonists
Lupus,
May 1, 2004;
13(5):
317 - 322.
[Abstract]
[PDF]
|
|
|
|
|
